Barone Francesca 4
4 · Candel Therapeutics, Inc. · Filed Mar 20, 2025
Insider Transaction Report
Form 4
Barone Francesca
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-03-18$8.76/sh−32,146$281,673→ 96,527 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-18−18,000→ 30,822 totalExercise: $1.55Exp: 2030-12-30→ Common Stock (18,000 underlying) - Exercise/Conversion
Common Stock
2025-03-18$1.55/sh+18,000$27,900→ 128,673 total
Footnotes (3)
- [F1]This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.345 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
- [F3]25% of the shares underlying this option vested and became exercisable on December 30, 2021, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.